Multiple Myeloma and Other Plasma Cell Neoplasms

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology, Oncology
Cover of the book Multiple Myeloma and Other Plasma Cell Neoplasms by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319255866
Publisher: Springer International Publishing Publication: February 16, 2018
Imprint: Springer Language: English
Author:
ISBN: 9783319255866
Publisher: Springer International Publishing
Publication: February 16, 2018
Imprint: Springer
Language: English

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

More books from Springer International Publishing

Cover of the book Metaheuristic Algorithms for Image Segmentation: Theory and Applications by
Cover of the book IR Playbook by
Cover of the book Philosophy of Race by
Cover of the book Modern Techniques and Solvents for the Extraction of Microbial Oils by
Cover of the book Queueing Theory and Network Applications by
Cover of the book Human Dynamics Research in Smart and Connected Communities by
Cover of the book Pulmonary Hypertension and Interstitial Lung Disease by
Cover of the book Difference Equations, Discrete Dynamical Systems and Applications by
Cover of the book Einstein's Photoemission by
Cover of the book Neoplastic Diseases of the Blood by
Cover of the book Time of Nature and the Nature of Time by
Cover of the book Advanced Computer and Communication Engineering Technology by
Cover of the book Toward the Next Generation of Bystander Prevention of Sexual and Relationship Violence by
Cover of the book Air Pollution Modeling and its Application XXV by
Cover of the book Stiff Extrusion Briquetting in Metallurgy by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy